Physician profile
James Breen
NPI 1851692800
$5,725.60
in general payments reported to CMS, 2019-2025
24 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $649 · 2023: $1,317 · 2024: $2,036 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,463 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.01 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,151.94 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $804.83 | 2021-2025 | |
| Genzyme Corporation | $721.92 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $392.80 | 2021-2024 | Odomzo, Blu-U |
| Amgen INC. | $382.82 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $377.67 | 2021-2025 | |
| Dermavant Sciences, INC. | $304.50 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $275.33 | 2021-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $252.07 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $229.15 | 2022-2024 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $185.18 | 2023-2024 | Zoryve |
| Pfizer INC. | $168.11 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2021 | |
| Galderma Laboratories, L.P. | $95.33 | 2022-2025 | Nemluvio, Aklief |
| Cipher Pharmaceuticals US LLC | $50.18 | 2025 | Natroba, Spinosad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $46.04 | 2025 | Vtama |
| Organogenesis INC. | $40.67 | 2025 | Puraply Wound Matrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.19 | 2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $23.89 | 2024 | Ycanth |
| Phadia US INC. | $21.45 | 2023 | Immunocap |
| Leo Pharma INC. | $19.23 | 2023 | Adbry |
| Smith+Nephew, INC. | $19.07 | 2022 | |
| Incyte Corporation | $16.83 | 2022 | |
| Almirall LLC | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.